These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23065626)

  • 21. Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.
    Dalla Via J; Daly RM; Owen PJ; Mundell NL; Rantalainen T; Fraser SF
    Bone; 2019 Oct; 127():367-375. PubMed ID: 31189088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients With Prostate Cancer.
    Morgan KM; Riviere P; Nelson TJ; Guram K; Deshler LN; Sabater Minarim D; Duran EA; Banegas MP; Rose BS
    JAMA Netw Open; 2024 Jun; 7(6):e2415911. PubMed ID: 38857047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.
    Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
    JAMA Intern Med; 2014 Sep; 174(9):1460-7. PubMed ID: 25023796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
    Ito K; Elkin EB; Girotra M; Morris MJ
    Ann Intern Med; 2010 May; 152(10):621-9. PubMed ID: 20479027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
    Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
    Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
    BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999.
    Zeliadt SB; Potosky AL; Etzioni R; Ramsey SD; Penson DF
    Urology; 2004 Dec; 64(6):1171-6. PubMed ID: 15596192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
    Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
    Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.
    Lee CE; Leslie WD; Lau YK
    BMC Cancer; 2012 Mar; 12():103. PubMed ID: 22436542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
    Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
    Elife; 2024 Apr; 13():. PubMed ID: 38656229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
    Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
    Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.